EYE1090
EYE1090 is an orally active VEGFR2 inhibitor with an IC50 of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization.
For research use only. We do not sell to patients.
- CAS No.: 3037217-70-9
- Formula: C22H26ClN7O2
- Molecular Weight:455.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
VEGFR-2 |
In Vitro
EYE1090 inhibits purified VEGFR2 kinase with an IC50 of 13 nM in the dark, and illumination enhances this potency to an IC50 of 3 nM[1].
EYE1090 (0.1-100 μM; 24 h) reduces NIH/3T3 fibroblast viability in a dose-dependent manner[1].
EYE1090 (50 min pre-incubation; 10 min light exposure; 4 h VEGF stimulation) inhibits VEGF-induced VEGFR2 signaling in VEGFR2/NFAT Reporter-HEK293 cells with an IC50 of 19.06 nM in the dark under cold white LED conditions, 21.75 nM under red LED conditions, and 33.37 nM under green LED conditions; illumination with cold white or green LED significantly enhances potency, while red LED has no effect[1].
EYE1090 (1-100 nM; 1 h pre-incubation; 10 min light exposure; 10 min VEGF stimulation) does not significantly inhibit VEGF-induced VEGFR2 phosphorylation at Y951 or Y1175 in VEGFR2/NFAT Reporter-HEK293 cells in the dark, but light exposure triggers potent inhibition of phosphorylation at these sites[1].
EYE1090 (0.1 nM-10 μM; 10 min pre-incubation; 10 min light exposure; 12 h incubation) inhibits HRMEC tubulogenesis with an IC50 of 410 nM in the dark, and light exposure enhances this potency to an IC50 of 133 nM, eliminating the potency gap with sunitinib[1].
EYE1090 (0.001-10 μM; 10 min pre-incubation; 10 min light exposure; 6 h migration incubation) inhibits HRMEC migration with an IC50 of 1012 nM in the dark, and light exposure enhances this potency to an IC50 of 474 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NIH/3T3 fibroblasts
-
Concentration:0.1; 1; 10; 50; 75; 100 μM
-
Incubation Time:24 h
-
Result:Reduced NIH/3T3 cell viability in a dose-dependent manner.
Was significantly less toxic than its parental compound sunitinib at concentrations above 75 μM (p<0.05).
-
Cell Line:VEGFR2/NFAT Reporter-HEK293 recombinant cell line
-
Concentration:1; 10; 50; 100 nM
-
Incubation Time:1 h pre-incubation; 10 min light exposure; 10 min VEGF stimulation
-
Result:Did not substantially inhibit VEGF-induced phosphorylation of VEGFR2 at Y951 or Y1175 in the dark, even at 100 nM.
Significantly suppressed VEGF-induced phosphorylation of VEGFR2 at Y951 or Y1175 with light exposure.
Left total VEGFR2 and β-actin levels unchanged, confirming no receptor degradation or loading differences.
In Vivo
EYE1090 (1 mg/kg; i.g.; daily; 3 days) significantly reduces VEGF-induced retinal vascular leakage in Long Evans rats[1].
EYE1090 (1 mg/kg; i.g.; daily; 3 days) significantly reduces choroidal neovascularization (CNV) lesion area in mice[1].
EYE1090 (40 mg/kg; i.g.; single dose) does not cause hepatotoxicity in mice under normal or dim red light conditions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cJRj mice (male, 8 weeks old)[1]
-
Dosage:40 mg/kg
-
Administration:i.g.; single dose
-
Result:Reduced mean serum concentrations by more than 50% in white light-exposed group compared to dark-treated controls.
Increased significantly in the dark condition.
Showed no significant increase in the light-exposed group.
-
Animal Model:Long Evans rats (male, 200-250 g) intravitreally injected with VEGF (50 ng/eye) on day3[1]
-
Dosage:1 mg/kg
-
Administration:i.g.; daily; 3 days
-
Result:Reduced VEGF-induced retinal vascular permeability significantly, with permeability values in VEGF-injected eyes significantly lower than those in VEGF-only control eyes.
Showed permeability values not significantly different from control eyes without VEGF injection.
-
Animal Model:Adlut C57BL/6JRj mice (9 weeks old) with choroidal neovascularization (CNV)[1]
-
Dosage:1 mg/kg
-
Administration:i.g.; daily; 3 days
-
Result:Reduced CNV lesion area highly significantly compared to vehicle controls by day 5.
Decreased lesion area through day 7, remaining significantly lower than vehicle controls.
-
Animal Model:BALB/cJRj (male and female, 6-10 weeks old)[1]
-
Dosage:40 mg/kg
-
Administration:i.g.; single dose
-
Result:Showed intact liver architecture, normal glycogen storage, and no evidence of necrosis, cellular stress, fibrosis, or abnormal collagen deposition under either normal light/dark cycles or continuous dim red light conditions.
Chemical Information
-
CAS No. 3037217-70-9
-
Molecular Weight 455.94
-
Formula C22H26ClN7O2
-
SMILES
CCN(CC)CCNC(C1=C(C)NC(/C=C2C(NC3=CC(Cl)=C(N=[N+]=[N-])C=C3\2)=O)=C1C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)